Aduro Biotech to Host Research and Development Day in New York
March 15 2017 - 9:00AM
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that the Aduro
management team will host a Research and Development Day in New
York City, New York, on Monday, March 27, 2017, at 8:30 a.m.
Eastern Time, to review its three distinct immunotherapy platform
technologies and related clinical programs. Leading
immunotherapy expert Thomas Gajewski M.D., Ph.D., leader of the
Immunology and Cancer program at the University of Chicago
Comprehensive Cancer Center, Director of Melanoma Oncology, and a
Professor in the Ben May Department for Cancer Research, will
present on the STING (Stimulator of Interferon Genes) pathway as an
important new therapeutic target and speak on its potential for
groundbreaking innovation in immunotherapy.
The following day, on Tuesday, March 28, Stephen T. Isaacs,
chairman, president and chief executive officer of Aduro, and
members of management, will ring the opening bell at the Nasdaq
Stock Market.
To access the live webcast and subsequent archived recording of
the Research and Development Day and other Aduro presentations,
please visit Aduro's website at www.aduro.com.
About Thomas Gajewski, M.D., Ph.D.Dr. Gajewski
is the leader of the Immunology and Cancer program at the
University of Chicago Comprehensive Cancer Center, Director of
Melanoma Oncology, and a Professor in the Ben May Department of
Cancer Research. His research interests include the role of the
STING pathway in immunity, the molecular and cellular regulation of
T lymphocyte activation and differentiation, and the application of
this information in immune-based cancer therapy. Dr. Gajewski has
published more than 200 papers in peer-reviewed journals on basic
aspects of T cell biology, anti-tumor immunity, and melanoma
therapy. He was formerly President of the Society for Immunotherapy
of Cancer, has served as an editor for Cancer Research and the
Journal for Immunotherapy of Cancer and has received numerous
awards and honors including the Burroughs Wellcome Fund Clinical
Scientist Award for Translational Research and the American Cancer
Society-Jules L. Plangere Jr. Family Foundation Professorship in
Cancer Immunotherapy.
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
mesothelioma, ovarian, lung and prostate cancers. Additionally, a
personalized form of LADD, or pLADD, is being developed utilizing
tumor neoantigens that are specific to an individual patient’s
tumor. Aduro's STING Pathway Activator platform is designed to
activate the STING receptor in immune cells, resulting in a potent
tumor-specific immune response. ADU-S100 is the first STING Pathway
Activator compound to enter the clinic and is currently being
evaluated in a Phase 1 study in patients with cutaneously
accessible metastatic solid tumors or lymphomas. Aduro’s B-select
monoclonal antibody platform includes a number of immune modulating
assets in research and preclinical development. Aduro is
collaborating with leading global pharmaceutical companies to
expand its products and technology platforms. For more information,
please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, our technology platforms, plans,
and the potential for eventual regulatory approval of our product
candidates. In some cases, you can identify these statements by
forward-looking words such as “may,” “will,” “continue,”
“anticipate,” “intend,” “could,” “project,” “seek,” “potential,”
“expect” or the negative or plural of these words or similar
expressions. Forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that
could cause actual results and events to differ materially from
those anticipated, including, but not limited to, our history of
net operating losses and uncertainty regarding our ability to
achieve profitability, our ability to develop and commercialize our
product candidates, our ability to use and expand our technology
platforms to build a pipeline of product candidates, our ability to
obtain and maintain regulatory approval of our product candidates,
our ability to operate in a competitive industry and compete
successfully against competitors that have greater resources than
we do, our reliance on third parties, and our ability to obtain and
adequately protect intellectual property rights for our product
candidates. We discuss many of these risks in greater detail
under the heading “Risk Factors” contained in our annual report on
Form 10-K for the year ended December 31, 2016, which is on file
with the Securities and Exchange Commission. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
Media Contact:
Susan Lehner
510 809 2137
press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024